Immunoglobulins in adult sepsis and septic shock

Current Infectious Disease Reports

Volumn 14, Issue 5, 2012, Pages 522-529

  Toussaint, Susanne ^a   Gerlach, Herwig ^a  

^a VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

Adjunctive therapy; Immunoglobulins; Sepsis; Septic shock; Severe sepsis; Therapy

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BLOODSTREAM INFECTION; CLINICAL TRIAL (TOPIC); DERMATOMYOSITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG QUALITY; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM POSITIVE INFECTION; GROUP A STREPTOCOCCAL INFECTION; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE ORGAN FAILURE; MYASTHENIA GRAVIS; ONSET AGE; OUTCOMES RESEARCH; POLYRADICULONEUROPATHY; POWDER; PRACTICE GUIDELINE; PUBLICATION; REVIEW; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; SYSTEMATIC ERROR; SYSTEMATIC REVIEW (TOPIC); TOXIC SHOCK SYNDROME;

EID: 84870555414     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0287-z     Document Type: Review

References (56)

1. Engel C, Brunkhorst FM, Bone H-G, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606-18. Excellent study with a randomized design to exclude biases such as hospital size, seasonal variations etc.
2. Karlsson S, Varpula M, Roukonen E, et al. Incidence, treatment and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435-43. EMEA Committee For Proprietary Medicinal Products: note for guidance on plasma-derived medicinal products. CPMP/BPWG/269/95. Ser. 2, London, 1998.
3. Europäisches Arzneibuch, Monograph No. 918: "Human Immunoglobulins for intravenous application". Edited by Govi Publisher, Eschborn, Germany, 3rd Edition, 1997.
4. Gaines A, Varricchio F, Kapit R. Renal insufficiency and failure associated with globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95:2523-9.
5. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602-7.
6. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107-16.
7. Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631-9.
8. Darenberg J, Söderquist B, Normark BH, Norrby-Teglund A. Differences in Potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis. 2004;38:836-42.
9. Schrage B, Duan G, Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 2006;43:743-6. Systematic analysis of the quality of different ivIG preparations demonstrating the potential impact on the design and outcome of clinical trials..
10. Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 1998;26:639-41.
11. Gitlin D, Janeway CA. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol. 1956;1:318-29.
12. Gitlin D, Gross PA, Janeway CA. The gamma globulins and their clinical significance. II. Hypogammaglobulinemia. N Engl J Med. 1959;260:72-6.
13. Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81-6.
14. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-55. First class review for readers that are interested in the broad field pathophysiology, pharmacodynamics, of clinical use of ivIG, especially in patients with inflammatory and autoimmune diseases..
15. Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003;24:S217-21.
16. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins -understanding properties and mechanisms. Clin Exp Immunol. 2009;158 Suppl 1:2-13. Our favorite review on the complex pathways by which ivIG preparations exert immunomodulatory effects..
17. Ramakrishna C, Newo ANS, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathogen. 2011;7:e1002071.
18. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol. 2008;45:4073-9.
19. Hartung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg) -beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158 Suppl 1:23-33. Excellent review especially for readers from the area of neurology and congenital syndromes where ivIG preparations are part of standard therapy.
20. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1-11.
21. Moiseeva KG, Nikiforova TV, Kharitonova AI, Koz'minykh LF, Pavlovskaia EN. Intravenous administration of immunoglobulins in young children with staphylococcal infections. Probl Gematol Pereliv Krovi. 1977;2:35-8.
22. Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia. Vox Sang. 1981;40:329-37.
23. Glinz W, Grob PJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med. 1985;11:288-94.
24. Cometta A, Baumgartner JD, Glauser MP. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol. 1994;97:69-72.
25. Fang KC. Monoclonal antibodies to endotoxin in the management of sepsis. West J Med. 1993;158:393-9.
26. Ziegler EJ, Fisher Jr. CJ, Sprung CL, et al. Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin -A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429-36. Definitely a "milestone" paper, although the results were disappointing. Readers will learn a lot!.
27. Albertson TE, Panacek EA, MacArthur RD, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med. 2003;31:419-27.
28. Christman JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest. 1992;102:613-7.
29. St John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock, and multiple-organ failure. Chest. 1993;103:932-43.
30. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebocontrolled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001;29:765-9.
31. Opal SM, Fisher Jr. CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115-24.
32. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:1369-76.
33. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome -A comparative observational study. Clin Infect Dis. 1999;28:800-7.
34. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333-40. The most important study on ivIG in streptococcal toxic shock syndrome, still being the base for recommendations for the use of ivIG in these patients..
35. Valiquette L, Low DE, McGeer AJ. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult question. Clin Infect Dis. 2009;49:1377-9.
36. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002;34:1084-93.
37. Bloos F, Reinhart K. New treatment approaches in sepsis. Zentralbl Chir. 2002;127:174-9.
38. Laupland KB. Polyclonal intravenous immunoglobulin for the treatment of infection in critically ill patients. Can J Infect Dis. 2002;13:100-6.
39. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090. http://www.ncbi.nlm.nih.gov/pubmed/11869591. Accessed 6 August 2012.
40. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39:38-46.
41. Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260:509-16.
42. Turgeon AF, Hutton B, Fergusson DA, et al. Metaanalysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146:193-203.
43. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-Analysis. Crit Care Med. 2007;35:2686-92. Although all of the metaanalyses from Ref. 41 to Ref. 48 are important, this one was performed in a sound matter..
44. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677-85.
45. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (review). Cochrane Library. 2010; doi:10.1002/14651858.CD001090. Together with Ref. 41, this review is the confirming analysis for the limited evidence on the use of ivIG in adult patients with sepsis.
46. Soares MO, Welton NJ, Harrison DA, et al. An evaluation of the feasibility, cost and value of information of a multicenter randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-Analysis and value of information analysis. Health Technol Assess. 2012;16:1-186. Definitely a "must" for everybody who wants sufficient information on this topic. Many sub-Analyses, many graphs, something like a "handbook" for EBM in severe sepsis..
47. Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med. 2007;35:2693-701. The most important RCTon ivIG in adult patients with severe sepsis..
48. Brocklehurst P, Farrell B, King A, for the INIS Collaborative Group, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365:1201-11. Extremely important, large RCT, although limited to very low weight newborns..
49. Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol. 1991;11:363-8.
50. Hentrich M, Fehnle K, Ostermann H, et al. IgM-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34:1319-25. The only available, good quality trial on the use of IgM-enriched ivIG in adult septic patients..
51. Rodriguez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23:298-304.
52. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281-6.
53. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev. 1997;9(Suppl):15-21.
54. Trzeciak S, Zanotti-Cavazzoni S, Parrillo JE, Dellinger RP. Inclusion criteria for clinical trials in sepsis: did the American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of sepsis have an impact? Chest. 2005;127:242-5.
55. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med. 1991;19:1104-13.
56. Baddley JW, DismukesWE. Chromoblastomycosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. New York: Springer Press; 2011. p. 427-33. Exhaustive review of chromoblastomycosis.